Dr. Karim Fizazi presented “Update on Mechanisms of Resistance in Castration-Resistant Prostate Cancer” at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal, between October 14th and 16th, 2016.

STOP-6 was accredited for CME by the European Accreditation Council for CME (UEMS-EACCME).

The meeting was organized by Bioscript and the Scientific Committee, composed of Professors Laurence Klotz (Chair), Noel Clarke, Karim Fizazi, and Bertrand Tombal.

Funding to support this educational activity was provided by FERRING Pharmaceuticals. FERRING did not influence meeting content and the views expressed during the meeting represent only those of the faculty.

 

Keywords: castration resistant prostate cancer, ADT, Abiraterone, Enzalutamide, taxanes

How to cite: Fizazi, Karim. “Update on Mechanisms of Resistance in Castration-Resistant Prostate Cancer” Grand Rounds in Urology. October 14-16, 2016. Accessed Mar 2021. https://grandroundsinurology.com/update-mechanisms-resistance-castration-resistant-prostate-cancer

This presentation was made at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal, between the 14th and 16th of October.

STOP-6 was accredited for CME by the European Accreditation Council for CME (UEMS-EACCME).

The meeting was organized by Bioscript and the Scientific Committee, composed of Professors Laurence Klotz (Chair), Noel Clarke, Karim Fizazi, and Bertrand Tombal.

Funding to support this educational activity was provided by FERRING Pharmaceuticals. FERRING did not influence meeting content and the views expressed during the meeting represent only those of the faculty.